Proinflammatory proteins S100A8/S100A9 activate NK cells via interaction with RAGE

Journal of Immunology

Volumn 194, Issue 11, 2015, Pages 5539-5548

  Narumi, Kenta ^a   Miyakawa, Reina ^a   Ueda, Ryosuke ^a   Hashimoto, Hisayoshi ^a   Yamamoto, Yuki ^a   Yoshida, Teruhiko ^a   Aoki, Kazunori ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CALGRANULIN A; CALGRANULIN B; GAMMA INTERFERON; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BENZAMIDE DERIVATIVE; FPS-ZM1; IMMUNOGLOBULIN RECEPTOR; NUCLEAR MATRIX PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; RAE1 PROTEIN, MOUSE; S100A8 PROTEIN, MOUSE; S100A9 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; IMMUNOLOGY; ISOGRAFT; NUDE MOUSE; PANCREAS TUMOR; TUMOR CELL LINE;

ANIMALS; BENZAMIDES; CALGRANULIN A; CALGRANULIN B; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; INFLAMMATION; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; NUCLEAR MATRIX-ASSOCIATED PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; PANCREATIC NEOPLASMS; RECEPTORS, IMMUNOLOGIC; TRANSPLANTATION, ISOGENEIC; TUMOR MICROENVIRONMENT;

EID: 84929646017     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402301     Document Type: Article

References (34)

1. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
2. Chan, C. J., M. J. Smyth, and L. Martinet. 2014. Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ. 21: 5-14.
3. Marçais, A., S. Viel, M. Grau, T. Henry, J. Marvel, and T. Walzer. 2013. Regulation of mouse NK cell development and function by cytokines. Front. Immunol. 4: 450.
4. Costantini, C., and M. A. Cassatella. 2011. The defensive alliance between neutrophils and NK cells as a novel arm of innate immunity. J. Leukoc. Biol. 89: 221-233.
5. Khammanivong, A., C. Wang, B. S. Sorenson, K. F. Ross, and M. C. Herzberg. 2013. S100A8/A9 (calprotectin) negatively regulates G2/M cell cycle progression and growth of squamous cell carcinoma. PLoS One 8: e69395. Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069395.
6. Pusterla, T., J. Nèmeth, I. Stein, L. Wiechert, D. Knigin, S. Marhenke, T. Longerich, V. Kumar, B. Arnold, A. Vogel, et al. 2013. Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology 58: 363-373.
7. Hiratsuka, S., A. Watanabe, H. Aburatani, and Y. Maru. 2006. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8: 1369-1375.
8. Mukhtar, R. A., A. P. Moore, V. J. Tandon, O. Nseyo, P. Twomey, C. A. Adisa, N. Eleweke, A. Au, F. L. Baehner, D. H. Moore, et al. 2012. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer. Ann. Surg. Oncol. 19: 3979-3986.
9. Grebhardt, S., C. Veltkamp, P. Ströbel, and D. Mayer. 2012. Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer. Int. J. Cancer 131: 2785-2794.
10. Kim, W. J., S. K. Kim, P. Jeong, S. J. Yun, I. C. Cho, I. Y. Kim, S. K. Moon, H. D. Um, and Y. H. Choi. 2011. A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol. Med. 17: 478-485.
11. Ichikawa, M., R. Williams, L. Wang, T. Vogl, and G. Srikrishna. 2011. S100A8/ A9 activate key genes and pathways in colon tumor progression. Mol. Cancer Res. 9: 133-148.
12. Spijkers-Hagelstein, J. A., P. Schneider, E. Hulleman, J. de Boer, O. Williams, R. Pieters, and R. W. Stam. 2012. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia 26: 1255-1265.
13. Choi, J. H., N. R. Shin, H. J. Moon, C. H. Kwon, G. H. Kim, G. A. Song, T. Y. Jeon, D. H. Kim, D. H. Kim, and Y. Park. 2012. Identification of S100A8 and S100A9 as negative regulators for lymph node metastasis of gastric adenocarcinoma. Histol. Histopathol. 27: 1439-1448.
14. Ohri, C. M., A. Shikotra, R. H. Green, D. A. Waller, and P. Bradding. 2011. The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC. PLoS One 6: e21874. Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021874.
15. Fan, B., L. H. Zhang, Y. N. Jia, X. Y. Zhong, Y. Q. Liu, X. J. Cheng, X. H. Wang, X. F. Xing, Y. Hu, Y. A. Li, et al. 2012. Presence of S100A9-positive inflammatory cells in cancer tissues correlates with an early stage cancer and a better prognosis in patients with gastric cancer. BMC Cancer 12: 316.
16. Jin, L., Q. Shen, S. Ding,W. Jiang, L. Jiang, and X. Zhu. 2012. Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy. Gynecol. Oncol. 126: 140-146.
17. Goldin, A., J. A. Beckman, A. M. Schmidt, and M. A. Creager. 2006. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114: 597-605.
18. Gebhardt, C., A. Riehl, M. Durchdewald, J. Németh, G. Fürstenberger, K. Müller-Decker, A. Enk, B. Arnold, A. Bierhaus, P. P. Nawroth, et al. 2008. RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med. 205: 275-285.
19. Ehrchen, J. M., C. Sunderkötter, D. Foell, T. Vogl, and J. Roth. 2009. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J. Leukoc. Biol. 86: 557-566.
20. Arumugam, T., V. Ramachandran, S. B. Gomez, A. M. Schmidt, and C. D. Logsdon. 2012. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin. Cancer Res. 18: 4356-4364.
21. Deane, R., I. Singh, A. P. Sagare, R. D. Bell, N. T. Ross, B. LaRue, R. Love, S. Perry, N. Paquette, R. J. Deane, et al. 2012. A multimodal RAGE-specific inhibitor reduces amyloid b-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 122: 1377-1392.
22. Kolaczkowska, E., and P. Kubes. 2013. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13: 159-175.
23. Mantovani, A., M. A. Cassatella, C. Costantini, and S. Jaillon. 2011. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11: 519-531.
24. Casanova-Acebes, M., N. A-González, L. A. Weiss, and A. Hidalgo. 2014. Innate immune cells as homeostatic regulators of the hematopoietic niche. Int. J. Hematol. 99: 685-694.
25. Gregory, A. D., and A. M. Houghton. 2011. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 71: 2411-2416.
26. Mócsai, A. 2013. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J. Exp. Med. 210: 1283-1299.
27. Srikrishna, G. 2012. S100A8 and S100A9: new insights into their roles in malignancy. J. Innate Immun. 4: 31-40.
28. Kasahara, M., and S. Yoshida. 2012. Immunogenetics of the NKG2D ligand gene family. Immunogenetics 64: 855-867.
29. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9: 495-502.
30. Xie, J., J. D. Méndez, V. Méndez-Valenzuela, and M. M. Aguilar-Hernández. 2013. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell. Signal. 25: 2185-2197.
31. Ott, C., K. Jacobs, E. Haucke, A. Navarrete Santos, T. Grune, and A. Simm. 2014. Role of advanced glycation end products in cellular signaling. Redox Biol. 2: 411-429.
32. Alves, M., V. C. Calegari, D. A. Cunha, M. J. Saad, L. A. Velloso, and E. M. Rocha. 2005. Increased expression of advanced glycation end-products and their receptor, and activation of nuclear factor kappa-B in lacrimal glands of diabetic rats. Diabetologia 48: 2675-2681.
33. Hiratsuka, S., A. Watanabe, Y. Sakurai, S. Akashi-Takamura, S. Ishibashi, K. Miyake, M. Shibuya, S. Akira, H. Aburatani, and Y. Maru. 2008. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 10: 1349-1355.
34. Cheng, P., C. A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, M. M. Bui, M. Ortiz, W. Nacken, C. Sorg, T. Vogl, et al. 2008. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205: 2235-2249.